2 research outputs found
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
No full textThe diagnosis of multiple myeloma (MM) has been associated to an increased risk of venous thromboembolic events (VTE). Described risk factors that are not exclusive to MM include old age, chemotherapy, immobility, high levels of vascular endothelial growth factor, cancer procoagulant and paraproteinemia. Disease-specific risk factors unique to MM are production of procoagulant autoantibodies, a high incidence of acquired activated protein C resistance, increased levels of factor VIII and von Willebrand factor, and increased production of inflammatory cytokines, mainly IL-6, TNF and C-reactive protein. Treatment regimens that include thalidomide or related compounds such as lenalidomide combined with glucocorticoids and-or cytotoxic chemotherapy were associated with an increased risk of VTE. The risk appears to be particularly high when these immunomodulatory agents are combined with anthracyclines as treatment of newly-diagnosed disease. Combinations including thalidomide plus dexamethasone and-or alkylating agents are associated with an intermediate risk. The same regimens for relapsed-refractory myeloma seem to be associated with a lower risk. The use of newer immunomodulators such as brotezomib seem to reduce the thrombogenic potential. Several different thromboprophylaxis strategies have been effective in lowering the risk of VTE but the data are disputable. None of these VTE prevention strategies have been prospectively compared head-to-head. © 2008 Elsevier Ltd. All rights reserved.Abdelkefi A, 2005, BONE MARROW TRANSPL, V36, P193, DOI 10.1038-sj.bmt.1705050; Abou-Jawde RM, 2006, MED ONCOL, V23, P263, DOI 10.1385-MO:23:2:263; Alikhan R, 2003, BLOOD COAGUL FIBRIN, V14, P341, DOI 10.1097-01.mbc.0000061310.06975.8e; Anagnostopoulos A, 2003, BRIT J HAEMATOL, V121, P768, DOI 10.1046-j.1365-2141.2003.04345.x; BARAD MJ, 2005, LEUKEMIA, V19, P154; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182-blood.V98.2.492; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056-NEJMoa053583; Baz R, 2005, MAYO CLIN PROC, V80, P1568; Baz R, 2006, ANN ONCOL, V17, P1766, DOI 10.1093-annonc-mdl313; Berenson JR, 2006, BRIT J HAEMATOL, V135, P174, DOI 10.1111-j.1365-2141.2006.06280.x; Berenson JR, 2004, CLIN LYMPHOMA, V5, P130, DOI 10.3816-CLM.2004.n.020; Berenson JR, 2007, CLIN CANCER RES, V13, P1762, DOI 10.1158-1078-0432.CCR-06-1812; Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001-jama.293.6.715; Caine GJ, 2002, NEOPLASIA, V4, P465, DOI 10.1038-sj.neo.7900263; CATOVSKY D, 1970, BRIT MED J, V3, P438; Cavo M, 2004, HAEMATOLOGICA, V89, P826; Chanan-Khan AA, 2008, J CLIN ONCOL, V26, P1544, DOI 10.1200-JCO.2007.14.5367; Ciolli S, 2006, LEUKEMIA LYMPHOMA, V47, P171, DOI 10.1080-10428190500272721; Corso A, 2004, ANN HEMATOL, V83, P588, DOI 10.1007-s00277-004-0891-6; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073-pnas.91.9.4082; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056-NEJMoa070594; Dimopoulos MA, 2004, HEMATOL J, V5, P112, DOI 10.1038-sj.thj.6200326; Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P252; Donati MB, 2001, ACTA HAEMATOL-BASEL, V106, P18, DOI 10.1159-000046585; Eby Charles, 2003, Curr Hematol Rep, V2, P388; Elice F, 2006, BRIT J HAEMATOL, V134, P399, DOI 10.1111-j.1365-2141.2006.06208.x; Esmon CT, 1999, BEST PRACT RES CL HA, V12, P343, DOI 10.1053-beha.1999.0029; FACON T, 2004, ASH ANN M ABSTR, V104, P206; Fuste B, 2002, THROMB HAEMOSTASIS, V88, P678; GABRIEL DA, 1983, J LAB CLIN MED, V101, P545; Galli M, 2004, HAEMATOLOGICA, V89, P1141; Garcia-Sanz R, 2004, LEUKEMIA, V18, P856, DOI 10.1038-sj.leu.2403322; Gouin-Thibault I, 2001, ACTA HAEMATOL-BASEL, V106, P33, DOI 10.1159-000046587; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001-archinte.160.6.809; Hovenga S, 2005, ANN HEMATOL, V84, P311, DOI 10.1007-s00277-004-0981-5; Hussein MA, 2006, MAYO CLIN PROC, V81, P889; Hussein MA, 2004, BRIT J HAEMATOL, V125, P470, DOI 10.1111-j-1365-2141.2004.04941.x; Ibrahim RB, 2005, BONE MARROW TRANSPL, V35, P1071, DOI 10.1038-sj.bmt.1704952; Ikhlaque N, 2006, AM J HEMATOL, V81, P420, DOI 10.1002-ajh.20625; Jones SC, 2005, ANN PHARMACOTHER, V39, P1249, DOI 10.1345-aph.1E654; Kaushal V, 2004, J THROMB HAEMOST, V2, P327, DOI 10.1046-j.1538-7933.2003.00573.x; Knight R, 2006, NEW ENGL J MED, V354, P2079; Kropff MH, 2003, BRIT J HAEMATOL, V122, P607, DOI 10.1046-j.1365-2141.2003.04473.x; Kumar RA, 2006, BIORHEOLOGY, V43, P681; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016-S0140-6736(94)90008-6; Li ZW, 2008, CURR OPIN HEMATOL, V15, P391, DOI 10.1097-MOH.0b013e328302c7f4; Lonial S, 2008, BRIT J HAEMATOL, V143, P222, DOI 10.1111-j.1365-2141.2008.07321.x; Mileshkin L, 2003, BLOOD, V102, P69, DOI 10.1182-blood-2002-09-2846; Minnema MC, 2004, LEUKEMIA, V18, P2044, DOI 10.1038-sj.leu.2403533; Moehler TM, 2001, BLOOD, V98, P3846, DOI 10.1182-blood.V98.13.3846; Morgan GJ, 2007, BRIT J HAEMATOL, V137, P268, DOI 10.1111-j.1365-2141.2007.06538.x; Neben K, 2002, CLIN CANCER RES, V8, P3377; Osman K, 2001, NEW ENGL J MED, V344, P1951, DOI 10.1056-NEJM200106213442516; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016-S0140-6736(06)68338-4; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182-blood-2007-10-117457; Palumbo A, 2007, J CLIN ONCOL, V25, P4459, DOI 10.1200-JCO.2007.12.3463; Popat R, 2008, BRIT J HAEMATOL, V141, P512, DOI 10.1111-j.1365-2141.2008.06997.x; Prince HM, 2005, CLIN CANCER RES, V11, P5504, DOI 10.1158-1078-0432.CCR-05-0213; Rajkumar SV, 2008, J CLIN ONCOL, V26, P2171, DOI 10.1200-JCO.2007.14.1853; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200-JCO.2002.02.116; Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200-JCO.2005.03.0221; Rajkumar SV, 2001, LEUKEMIA, V15, P1274, DOI 10.1038-sj.leu.2402183; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038-sj.leu.2402866; Rajkumar SV, 2005, BLOOD, V106, P4050, DOI 10.1182-blood-2005-07-2817; Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111; RICHARDSON P, 2005, ASH ANN M ABSTR, V106, P365; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182-blood-2002-03-0996; Richardson PG, 2006, EXPERT REV ANTICANC, V6, P1165, DOI 10.1586-14737140.6.8.1165; Richardson PG, 2008, EXPERT REV ANTICANC, V8, P1053, DOI 10.1586-14737140.8.7.1053; Sallah S, 2004, ANN ONCOL, V15, P1490, DOI 10.1093-annonc-mdh385; Sanderink GJCM, 2002, THROMB RES, V105, P225, DOI 10.1016-S0049-3848(02)00031-2; Schey SA, 2003, LEUKEMIA RES, V27, P909, DOI 10.1016-S0145-2126(03)00027-4; Schutt P, 2005, EUR J HAEMATOL, V74, P40, DOI 10.1111-j.1600-0609.2004.00349.x; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056-NEJM199911183412102; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056-NEJM199804233381701; Srkalovic G, 2004, CANCER, V101, P558, DOI 10.1002-cncr.20405; TABU M, 2004, CLIN APPL THROMB-HEM, V10, P225; Tallman Martin S, 2004, Rev Clin Exp Hematol, V8, pE1; TERPOS E, 2008, LEUKEMIA 0904; Urbauer E, 2002, BLOOD, V99, P4247, DOI 10.1182-blood-2001-12-0245; Valdre L., 2003, Pathophysiology of Haemostasis and Thrombosis, V33, P70; Wang M, 2005, AM J HEMATOL, V79, P194, DOI 10.1002-ajh.20382; WARD CM, 2003, HEMATOL J, V4; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200-JCO.2003.03.139; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056-NEJMoa070596; Yasin Z, 1999, AM J HEMATOL, V62, P99, DOI 10.1002-(SICI)1096-8652(199910)62:299::AID-AJH63.0.CO;2-N; Zangari M, 2001, BLOOD, V98, P1614, DOI 10.1182-blood.V98.5.1614; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182-blood-2002-01-0335; Zangari M, 2007, SEMIN THROMB HEMOST, V33, P339, DOI 10.1055-s-2007-976169; ZANGARI M, 2004, BLOOD, V104, pA13; Zangari M, 2003, SEMIN THROMB HEMOST, V29, P275; Zangari M, 2004, BRIT J HAEMATOL, V126, P715, DOI 10.1111-j.1365-2141.2004.05078.x; Zervas K, 2004, ANN ONCOL, V15, P134, DOI 10.1093-annonc-mdh026; Zonder JA, 2006, BLOOD, V108, P403, DOI 10.1182-blood-2006-01-015427242
Determinism and organization. Foundations and limits of Claude Bernard’s program
No full textComo lo afirma el autor de este perspicazlibro: el presente de una ciencia no solamente se define por su éxito y su proyección, también hacen parte de su imagen más completa -aunque precisamente por eso jamás acabada- los problemas y polémicas de dicha ciencia; asuntos que la mantienen activa, creativa y avanzando.
Este libro se constituye en una franca imagen del presente de una ciencia como la Biología. Magistralmente Gustavo Caponi examina, a la luz de los problemas y tensiones actuales de la Filosofía de la Biología, la historia del programa de la Fisiología Experimental conformado en el siglo XIX por el médico y biólogo francés Claude Bernard. Así, el objeto de este libro es al menos doble: por un lado, examinar con detalle y ofrecer claridad de los presupuestos y consecuencias epistemológicas de la Fisiología Experimental de Claude Bernard; por otro, valerse de las discusiones históricas de la Biología para traer nuevas respuestas y precisiones al actual debate presente en la Filosofía de la Biología.The present of a science is not only defined by its success and projection; the problems and controversies that keep it moving forward are also part of its complete image. This book constitutes a frank image of the present of Biology. The author examines, in light of the current problems of the philosophy of biology, the history of the program of experimental physiology elaborated in the 19th century by the French scientist Claude Bernard
